Webinar#2: Advancing Lipid-Based Drug Delivery with Maisine® CC and LiGlass™
Collaborative webinar series with GatteFosse
Improved Bioavailability of ARV-110 by 5.6x
ARV-110 Case Study: Solubility Enhancement Formulation Using SeraNovo’s GlassE Formulation Platform Delve into the details of how SeraNovo’s formulation achieved a 5.6x improvement in bioavailability for ARV-110. This case study…
Article 4: Impact of Formulations in Drug Development
Exploring the Role of Formulations in Enhancing Drug Development Drug development has undergone several changes over the years, organisations have capacities to screen an abundance of targets and compounds and…
Sustainability in Pharma: Lower your CO2 emissions by over 90%
This case study analyzes CO₂ emissions for manufacturing a 10 kg batch of pharmaceuticals, comparing SeraNovo’s liquid formulation to SSD Pharmaceutical companies are under increasing pressure to adopt sustainable manufacturing…
Formulation Development With SeraNovo’s Cutting Edge Solutions
Insights from the Case Study of Glibenclamide Formulation scientists globally face a significant challenge due to the low aqueous solubility of many active pharmaceutical ingredients. While current solutions like amorphous…
Article 3: Overcoming the Hurdles of Oral Peptide Delivery
Overcoming Challenges for Oral Peptide Absorption Why oral delivery of peptides? Peptides consist of amino acids linked together through amide bonds, like beads on a chain. Because of the chemical…
What The Flux: The Impact of Formulations
The Impact of Formulations on the Absorption of Poorly Soluble Drugs from the Gastro-Intestinal Tract. A drug is considered poorly soluble when it fails to generate the concentration in the…
Article 2: Overcoming Formulation Challenges in Targeted Protein Degraders
The pharmaceutical industry is increasingly focusing on the development of protein degraders, particularly Proteolysis Targeting Chimeras (PROTACs), as a novel therapeutic approach. These small molecules have shown great promise in…